Progyny (PGNY) Projected to Post Earnings on Tuesday

Progyny (NASDAQ:PGNY) is expected to be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect Progyny to post earnings of $0.36 per share and revenue of $277.31 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Progyny Stock Up 1.9 %

NASDAQ:PGNY opened at $22.36 on Tuesday. Progyny has a twelve month low of $13.39 and a twelve month high of $42.08. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of 38.55, a price-to-earnings-growth ratio of 2.18 and a beta of 1.34. The stock’s 50 day moving average price is $19.19 and its two-hundred day moving average price is $18.64.

Insider Transactions at Progyny

In related news, CEO Peter Anevski purchased 209,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the purchase, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman David J. Schlanger purchased 150,000 shares of Progyny stock in a transaction that occurred on Thursday, December 26th. The shares were bought at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now directly owns 228,269 shares of the company’s stock, valued at $3,350,988.92. This represents a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on PGNY shares. Bank of America upped their price target on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Barclays dropped their target price on shares of Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Truist Financial reiterated a “hold” rating and set a $19.00 price target (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Finally, Canaccord Genuity Group reduced their target price on Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a research note on Wednesday, November 13th. Nine equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $25.83.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.